Search research articles
Contact Us
Filters
Showing results (11-20 of 87) with videos related to
Page
of 9
Sort By:
Oncology Letters
|
April 26, 2014
<i>KRAS</i> and <i>BRAF</i> genotyping of synchronous colorectal carcinomas
Riccardo Giannini, Cristiana Lupi, Fotios Loupakis, et al.
Cancer Treatment Reviews
|
March 25, 2022
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features
Marco Maria Germani, Beatrice Borelli, Piero Boraschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2020
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini, Carlotta Antoniotti, Alexander Stein, et al.
Investigational New Drugs
|
March 1, 2018
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients
Teresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
Biochemical Pharmacology
|
April 7, 2019
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics
Teresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
The Pharmacogenomics Journal
|
February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.
Critical Reviews in Oncology/Hematology
|
April 14, 2023
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm
Beatrice Borelli, Marco Maria Germani, Martina Carullo, et al.
British Journal of Cancer
|
June 21, 2017
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
Laura Demurtas, Marco Puzzoni, Riccardo Giampieri, et al.
Surgical Oncology
|
August 23, 2022
Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study
Roberto Moretto, Beatrice Borelli, Piero Boraschi, et al.
Clinical Colorectal Cancer
|
April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study
Alessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 87) with videos related to
Sort By:
Page
of 9
Oncology Letters
|
April 26, 2014
<i>KRAS</i> and <i>BRAF</i> genotyping of synchronous colorectal carcinomas
Riccardo Giannini, Cristiana Lupi, Fotios Loupakis, et al.
Cancer Treatment Reviews
|
March 25, 2022
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features
Marco Maria Germani, Beatrice Borelli, Piero Boraschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2020
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini, Carlotta Antoniotti, Alexander Stein, et al.
Investigational New Drugs
|
March 1, 2018
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients
Teresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
Biochemical Pharmacology
|
April 7, 2019
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics
Teresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
The Pharmacogenomics Journal
|
February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.
Critical Reviews in Oncology/Hematology
|
April 14, 2023
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm
Beatrice Borelli, Marco Maria Germani, Martina Carullo, et al.
British Journal of Cancer
|
June 21, 2017
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
Laura Demurtas, Marco Puzzoni, Riccardo Giampieri, et al.
Surgical Oncology
|
August 23, 2022
Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study
Roberto Moretto, Beatrice Borelli, Piero Boraschi, et al.
Clinical Colorectal Cancer
|
April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study
Alessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
Page
of 9